Reports

Sale

Infectious Disease Molecular Diagnostics Market

Global Infectious Disease Molecular Diagnostics Market Size: By Product: Instruments, Reagents, Services; By Technology: Polymerase Chain Reaction (PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Others; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Infectious Disease Molecular Diagnostics Market Size

The global infectious disease molecular diagnostics market was valued at USD 35.87 billion in 2023, driven by the increasing geriatric population, rising incidence of infectious diseases and technological advancements in diagnostics devices across the globe. The market is expected to grow at a CAGR of 3.20% during the forecast period of 2024-2032, with the values likely to attain USD 47.62 billion by 2032.

 

infectious disease molecular diagnostics market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Infectious Disease Molecular Diagnostics Market Outlook

  • According to an article published by World Health Organization, an estimated 354 million people worldwide live with hepatitis B or C. The rising prevalence of infectious diseases globally, such as HIV/AIDS, hepatitis, tuberculosis, and respiratory infections and advances in molecular diagnostic technologies are the major drivers for the growth of the market.
  • The government initiatives, screening programs and awareness campaigns aimed at controlling the spread of infectious diseases are propelling the market growth. These efforts emphasize the importance of early detection and treatment, spurring the adoption of molecular diagnostics technologies.
  • The advances in molecular diagnostic technologies, such as PCR (polymerase chain reaction), nucleic acid amplification techniques, have revolutionized infectious disease diagnostics, which leads to increase in market growth.

 

Global Infectious Disease Molecular Diagnostics Market Overview

Infectious disease molecular diagnostic devices include specialized instruments or platforms designed for the detection and identification of infectious agents, such as viruses, bacteria, fungi, and parasites, through molecular methods. These devices employ various molecular diagnostic technologies to amplify and analyze nucleic acids (e.g., DNA or RNA) specific to pathogens present in clinical samples obtained from patients.

 

The global burden of infectious diseases continues to increase due to factors such as population growth and antimicrobial resistance. As a result, there is a growing need for accurate and rapid diagnostic tests to identify pathogens responsible for infection. Moreover, governments, healthcare systems, public health agencies are investing in molecular diagnostics to enhance their capacity for early detection, surveillance, and containment of outbreaks.

 

There is a growing demand for point-of-care (POCT) molecular diagnostic tests that can deliver rapid results at the bedside or in community settings. POCT solutions enable timely diagnosis, treatment initiation, and containment of infectious diseases, particularly in resource-limited areas which is expected to create great opportunities for the growth of the market.

 

Global Infectious Disease Molecular Diagnostics Market Growth Drivers

Rising Demand for Diagnostics Solution

As the incidence of infectious diseases increases, there is a corresponding rise in the demand for diagnostic solutions to identify pathogens causing these diseases. Molecular diagnostics offer high sensitivity and specificity, enabling healthcare providers to detect infectious agents with greater accuracy than traditional methods, such as culture-based techniques.

 

In the face of outbreaks or epidemics, early detection and surveillance are crucial for controlling the spread of infectious diseases. Molecular diagnostics facilitate early identification of pathogens, allowing for prompt intervention measures. The urgency to contain outbreaks drives the adoption of molecular diagnostic tests, thereby boosting market value.

 

Surge in Infectious Diseases

According to the World Health Organization’s (WHO) annual estimates, there are globally 300–500 million cases of malaria, 333 million cases of sexually transmitted diseases (syphilis, gonorrhea, chlamydia, and trichomonas), 33 million cases of HIV/AIDS, 14 million people infected with tuberculosis, and 3–5 million cases of cholera. The increase in infectious diseases driving demand for diagnostic solutions, prompting technological advancements, expanding testing capabilities, attracting funding, and raising public awareness about the importance of early detection and surveillance.

 

Increasing Technological Innovations Expected to Propel Infectious Disease Molecular Diagnostics Market Demand

Technological advancements play a pivotal role in driving growth in the market of infectious disease molecular diagnostics by enhancing the performance, accessibility, and versatility of diagnostic tests. Techniques such as real-time PCR, digital PCR, and next-generation sequencing (NGS) enable the detection of low levels of pathogens in clinical samples, improving diagnostic accuracy and reducing false-negative results. Multiplex assays allow the simultaneous detection of multiple pathogens or genetic targets in a single test, offering significant time and cost savings compared to traditional single-target assays.

 

Hence, the technological advancements continue to shape the landscape of infectious disease molecular diagnostics, driving innovation, improving performance, and expanding the market growth.

 

infectious disease molecular diagnostics market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Infectious Disease Molecular Diagnostics Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

 

Key Trends Key Trends
Expansion of Point-of-Care Testing There's a growing trend towards the adoption of point of care molecular diagnostics, driven by the need for rapid and decentralized testing. Advancements such as portable molecular diagnostic devices are being developed to enable on-site testing in various settings, including clinics, emergency departments, and remote areas with limited access to laboratory facilities, contributing to market growth. For instance, several RT-PCR systems that use micro fluidic technology including Cepheid GeneXpert have been granted the clinical laboratory improvement amendment (CLIA) waiver by the United States Food and Drug administration (FDA), which allowing their use in POC settings.
Integration of Next Generation Sequencing Next-generation sequencing (NGS) technologies are increasingly being integrated into infectious disease molecular diagnostics workflows, enabling comprehensive genomic analysis of pathogens. NGS offers insights into pathogen evolution, antimicrobial resistance, and outbreak investigation, driving its adoption in clinical and public health settings. The increasing technological advancements are augmenting the growth of the market.
Rise in Strategic Partnerships The infectious disease molecular diagnostics market value is influenced by strategic mergers and acquisitions activities among manufacturers, healthcare providers, and technology companies that are driving innovation and fostering market expansion. These collaborations are accelerating the development of advanced products and augmenting the market reach globally. For instance, in April 2023, ALPCO-GeneProof and Thermo F isher announced a strategic partnership intended to bring TaqPath Menu-GeneProof PCR kits to the market. The partnership combined the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust supply chain and support systems.

 

Global Infectious Disease Molecular Diagnostics Market Segmentation

Market Breakup by Product

  • Instruments
    • Benchtop
    • Portable
  • Reagents
  • Services

 

Market Breakup by Technology

  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • Transcription Mediated Amplification
  • Others

 

Market Breakup by Application

  • Respiratory Diseases
  • Gastrointestinal Tract Infections
  • Sexually Transmitted Infections
  • Drug Resistance Diseases
  • Others

 

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Infectious Disease Molecular Diagnostics Market Share

Market Segmentation Based on Technology is Anticipated to Witness Substantial Growth

By technology, the market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), chips and microarrays, mass spectrometry, sequencing, transcription mediated amplification and others. The polymerase chain reaction (PCR) segment is dominating the market as it is one of the most widely used and established technologies in infectious disease molecular diagnostics. It allows for the amplification and detection of specific DNA or RNA sequences of pathogens with high sensitivity and specificity. Real-time PCR enables quantitative measurement of target nucleic acids and is commonly used for viral load monitoring and detection of bacterial, viral, and fungal infections.

 

infectious disease molecular diagnostics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Infectious Disease Molecular Diagnostics Market Analysis by Region

Based on region, the market covers North America, Europe, Asia Pacific, Latin America, as well as Middle East and Africa. North America is dominating the market share due to increasing technological innovation. North America, particularly United States is a leading hub for innovation and research in molecular diagnostics. Moreover, the government agencies, and private investors in North America allocate significant funding and resources to support research and development in infectious disease diagnostics market.

 

Europe also holds a significant infectious disease molecular diagnostics market value due to region's robust healthcare infrastructure supports the adoption and integration of molecular diagnostic technologies into routine clinical practice, facilitating widespread testing for infectious diseases across various healthcare settings. Additionally, Asia Pacific is expected to witness substantial market growth fueled by the growing patient pool suffering from infectious diseases and increasing collaboration and funding initiatives.

 

Leading Players in the Global Infectious Disease Molecular Diagnostics Market

The key features of the market report include patent analysis and strategic initiatives including partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:

 

Becton, Dickinson and Company

BD is a leading global medical technology company that offers a wide range of products and solutions, including infectious disease molecular diagnostic devices. BD has a significant presence in the infectious disease molecular diagnostics market, offering innovative solutions to healthcare providers, laboratories, and public health agencies worldwide.

 

BioMérieux SA

BioMérieux is a prominent global leader in in-vitro diagnostics, including molecular diagnostics for infectious diseases. The company offers a range of innovative molecular diagnostic devices designed to detect and identify pathogens with accuracy and efficiency.

 

QIAGEN

QIAGEN is a leading global provider of molecular diagnostics solutions, offering a range of innovative products and platforms for the detection and identification of infectious diseases.

 

Other key players in the market include F. Hoffmann-La Roche Ltd., Abbott, Agilent Technologies, Inc., Danaher Corporation, Hologic, Inc., Sysmex Corporation, and Illumina, Inc. among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Technology
  • Application
  • End User
  • Region
Breakup by Product
  • Instruments
  • Reagents
  • Services
Breakup by Technology
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • Transcription Mediated Amplification
  • Others 
Breakup by Application
  • Respiratory Diseases
  • Gastrointestinal Tract Infections
  • Sexually Transmitted Infections
  • Drug Resistance Diseases
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Becton, Dickinson and Compa
  • bioMérieux SA 
  • QIAGEN
  • F. Hoffmann-La Roche Ltd 
  • Abbott 
  • Danaher Corporation 
  • Agilent Technologies, Inc.
  • Hologic, Inc. 
  • Sysmex Corporation 
  • Illumina, Inc.

 

Key Questions Answered in the Global Infectious Disease Molecular Diagnostics Market Report

  • What was the global infectious disease molecular diagnostics market value in 2023?
  • What is the global infectious disease molecular diagnostics market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on product?
  • What is market segmentation based on technology?
  • What is market segmentation based on application?
  • What are the major factors aiding the global infectious disease molecular diagnostics market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major market trends influencing the market? 
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How does the prevalence of infectious diseases affect the market landscape?
  • How does the growing technological advancements impact the market size?
  • How do the increasing trend of POC testing affect the market landscape?
  • Which application area is expected to have a high market value in the coming years?
  • Who are the key players involved in the infectious disease molecular diagnostics market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Infectious Disease Molecular Diagnostics Market Overview 

    3.1    Global Infectious Disease Molecular Diagnostics Market Historical Value (2017-2023) 
    3.2    Global Infectious Disease Molecular Diagnostics Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Global Infectious Disease Molecular Diagnostics Market Landscape*
    5.1    Global Infectious Disease Molecular Diagnostics: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    Global Infectious Disease Molecular Diagnostics: Product Landscape 
        5.2.1    Analysis by Product
        5.2.2    Analysis by Technology
6    Global Infectious Disease Molecular Diagnostics Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis
        6.3.1    Political
        6.3.2    Economic
        6.3.3    Social
        6.3.4    Technological
        6.3.5    Legal
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    Global Infectious Diseases Molecular Diagnostics Market, Epidemiology Snapshot
    7.1    Overview of Global Infectious Disease Incidence Number (2017-2032)
    7.2    Incidence Number, By Indication (2017-2032)
        7.2.1    Respiratory Diseases
        7.2.2    Gastrointestinal Tract Infections
        7.2.3    Sexually Transmitted Infections
        7.2.4    Others
8    Global Infectious Disease Molecular Diagnostics Market Segmentation (2017-2032)
    8.1    Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        8.1.1    Market Overview
        8.1.2    Instruments
            8.1.2.1    Benchtop
            8.1.2.2    Portable
        8.1.3    Reagents
        8.1.4    Services
    8.2    Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        8.2.1    Market Overview
        8.2.2    Polymerase Chain Reaction (PCR)
        8.2.3    In Situ Hybridization
        8.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        8.2.5    Chips and Microarrays
        8.2.6    Mass Spectrometry
        8.2.7    Sequencing
        8.2.8    Transcription Mediated Amplification
        8.2.9    Others 
    8.3    Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        8.3.1    Market Overview
        8.3.2    Respiratory Diseases
        8.3.3    Gastrointestinal Tract Infections
        8.3.4    Sexually Transmitted Infections
        8.3.5    Drug Resistance Diseases
        8.3.6    Others
    8.4    Global Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        8.4.1    Market Overview
        8.4.2    Hospitals
        8.4.3    Specialty Clinics
        8.4.4    Diagnostic Laboratories
        8.4.5    Research Institutes
        8.4.6    Others
    8.5    Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Region
        8.5.1    Market Overview
        8.5.2    North America
        8.5.3    Europe 
        8.5.4    Asia Pacific
        8.5.5    Latin America
        8.5.6    Middle East and Africa
9    North America Infectious Disease Molecular Diagnostics Market (2017-2032)
    9.1    North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        9.1.1    Market Overview
        9.1.2    Instruments
            9.1.2.1    Benchtop
            9.1.2.2    Portable
        9.1.3    Reagents
        9.1.4    Services
    9.2    North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        9.2.1    Market Overview
        9.2.2    Polymerase Chain Reaction (PCR)
        9.2.3    In Situ Hybridization
        9.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        9.2.5    Chips and Microarrays
        9.2.6    Mass Spectrometry
        9.2.7    Sequencing
        9.2.8    Transcription Mediated Amplification
        9.2.9    Others 
    9.3    North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        9.3.1    Market Overview
        9.3.2    Respiratory Diseases
        9.3.3    Gastrointestinal Tract Infections
        9.3.4    Sexually Transmitted Infections
        9.3.5    Drug Resistance Diseases
        9.3.6    Others
    9.4    North America Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        9.4.1    Market Overview
        9.4.2    Hospitals
        9.4.3    Specialty Clinics
        9.4.4    Diagnostic Laboratories
        9.4.5    Research Institutes
        9.4.6    Others
    9.5    North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
        9.5.1    United States of America
        9.5.2    Canada
10    Europe Infectious Disease Molecular Diagnostics Market (2017-2032)
    10.1    Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        10.1.1    Market Overview
        10.1.2    Instruments
            10.1.2.1    Benchtop
            10.1.2.2    Portable
        10.1.3    Reagents
        10.1.4    Services
    10.2    Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        10.2.1    Market Overview
        10.2.2    Polymerase Chain Reaction (PCR)
        10.2.3    In Situ Hybridization
        10.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        10.2.5    Chips and Microarrays
        10.2.6    Mass Spectrometry
        10.2.7    Sequencing
        10.2.8    Transcription Mediated Amplification
        10.2.9    Others 
    10.3    Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        10.3.1    Market Overview
        10.3.2    Respiratory Diseases
        10.3.3    Gastrointestinal Tract Infections
        10.3.4    Sexually Transmitted Infections
        10.3.5    Drug Resistance Diseases
        10.3.6    Others
    10.4    Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        10.4.1    Market Overview
        10.4.2    Hospitals
        10.4.3    Specialty Clinics
        10.4.4    Diagnostic Laboratories
        10.4.5    Research Institutes
        10.4.6    Others
    10.5    Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
        10.5.1    United Kingdom
        10.5.2    Germany
        10.5.3    France
        10.5.4    Italy
        10.5.5    Others
11    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032)
    11.1    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        11.1.1    Market Overview
        11.1.2    Instruments
            11.1.2.1    Benchtop
            11.1.2.2    Portable
        11.1.3    Reagents
        11.1.4    Services
    11.2    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        11.2.1    Market Overview
        11.2.2    Polymerase Chain Reaction (PCR)
        11.2.3    In Situ Hybridization
        11.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        11.2.5    Chips and Microarrays
        11.2.6    Mass Spectrometry
        11.2.7    Sequencing
        11.2.8    Transcription Mediated Amplification
        11.2.9    Others 
    11.3    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        11.3.1    Market Overview
        11.3.2    Respiratory Diseases
        11.3.3    Gastrointestinal Tract Infections
        11.3.4    Sexually Transmitted Infections
        11.3.5    Drug Resistance Diseases
        11.3.6    Others
    11.4    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        11.4.1    Market Overview
        11.4.2    Hospitals
        11.4.3    Specialty Clinics
        11.4.4    Diagnostic Laboratories
        11.4.5    Research Institutes
        11.4.6    Others
    11.5    Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
        11.5.1    China
        11.5.2    Japan
        11.5.3    India
        11.5.4    ASEAN
        11.5.5    Australia
        11.5.6    Others
12    Latin America Infectious Disease Molecular Diagnostics Market (2017-2032)
    12.1     Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        12.1.1    Market Overview
        12.1.2    Instruments
            12.1.2.1    Benchtop
            12.1.2.2    Portable
        12.1.3    Reagents
        12.1.4    Services
    12.2    Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        12.2.1    Market Overview
        12.2.2    Polymerase Chain Reaction (PCR)
        12.2.3    In Situ Hybridization
        12.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        12.2.5    Chips and Microarrays
        12.2.6    Mass Spectrometry
        12.2.7    Sequencing
        12.2.8    Transcription Mediated Amplification
        12.2.9    Others 
    12.3    Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        12.3.1    Market Overview
        12.3.2    Respiratory Diseases
        12.3.3    Gastrointestinal Tract Infections
        12.3.4    Sexually Transmitted Infections
        12.3.5    Drug Resistance Diseases
        12.3.6    Others
    12.4    Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        12.4.1    Market Overview
        12.4.2    Hospitals
        12.4.3    Specialty Clinics
        12.4.4    Diagnostic Laboratories
        12.4.5    Research Institutes
        12.4.6    Others
    12.5    Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
        12.5.1    Brazil
        12.5.2    Argentina
        12.5.3    Mexico
        12.5.4    Others
13    Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032)
    13.1     Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
        13.1.1    Market Overview
        13.1.2    Instruments
            13.1.2.1    Benchtop
            13.1.2.2    Portable
        13.1.3    Reagents
        13.1.4    Services
    13.2    Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
        13.2.1    Market Overview
        13.2.2    Polymerase Chain Reaction (PCR)
        13.2.3    In Situ Hybridization
        13.2.4    Isothermal Nucleic Acid Amplification Technology (INAAT)
        13.2.5    Chips and Microarrays
        13.2.6    Mass Spectrometry
        13.2.7    Sequencing
        13.2.8    Transcription Mediated Amplification
        13.2.9    Others 
    13.3    Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
        13.3.1    Market Overview
        13.3.2    Respiratory Diseases
        13.3.3    Gastrointestinal Tract Infections
        13.3.4    Sexually Transmitted Infections
        13.3.5    Drug Resistance Diseases
        13.3.6    Others
    13.4    Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
        13.4.1    Market Overview
        13.4.2    Hospitals
        13.4.3    Specialty Clinics
        13.4.4    Diagnostic Laboratories
        13.4.5    Research Institutes
        13.4.6    Others
    13.5    Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
        13.5.1    Saudi Arabia
        13.5.2    United Arab Emirates
        13.5.3    Nigeria
        13.5.4    South Africa
        13.5.5    Others
14    Regulatory Framework
    14.1    Regulatory Overview
    14.2    US FDA
    14.3    EU EMA
    14.4    INDIA CDSCO
    14.5    JAPAN PMDA
    14.6    Others
15    Patent Analysis
    15.1     Analysis by Type of Patent
    15.2     Analysis by Publication Year
    15.3     Analysis by Issuing Authority
    15.4     Analysis by Patent Age
    15.5     Analysis by CPC Analysis
    15.6     Analysis by Patent Valuation 
    15.7     Analysis by Key Players
16    Strategic Initiatives
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership and Collaborations
    16.3    Analysis by Joint Ventures
    16.4    Analysis by Leading Players
    16.5    Analysis by Geography 
17    Supplier  Landscape
    17.1    Market Share Analysis, By Region (Top 5 Companies)
        17.1.1    Market Share Analysis: Global
        17.1.2    Market Share Analysis: North America
        17.1.3    Market Share Analysis: Europe
        17.1.4    Market Share Analysis: Asia-Pacific
        17.1.5    Market Share Analysis: Others
    17.2    Becton, Dickinson and Company 
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications 
    17.3    bioMérieux SA   
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    QIAGEN 
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    F. Hoffmann-La Roche Ltd 
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Abbott 
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Danaher Corporation 
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Agilent Technologies, Inc. 
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Hologic, Inc. 
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Sysmex Corporation 
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Illumina, Inc. 
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
18    Global Infectious Disease Molecular Diagnostics Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 

19    Key Opinion Leaders (KOL) Insights (Additional Insight)

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER